And there we have the correct date.
4Q 2021.
I don't know what to say kids. Management are outdoing themselves.
Cheap buy-in on first tendon stem-cell study of its kind in conjunction with the largest Pharma in the world. But I've been echoing that crap for years now, so its a bit hollow.
Bio-techs with great products and poor management. I've had my fill of them and they've cost me financially.
These are great products that can help so many patients with unmet needs. I can only hope J&J see the potential I do.
Ann: Ortho-ATI Shoulder Tendon Study Update Revised, page-2
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.5¢ |
Change
0.115(20.9%) |
Mkt cap ! $134.1M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 67.0¢ | 56.5¢ | $1.736M | 2.771M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42825 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 29226 | 1 |
View Market Depth
| Last trade - 15.41pm 10/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |